Drug Type CAR-NK |
Synonyms Anti-CLL1/CD33 CAR T Cell(Guangzhou Bio-gene Technology), CLL1/CD33 CAR-T(Guangzhou Bio-gene Technology), IBR733 |
Target |
Action modulators |
Mechanism CD33 modulators(Myeloid cell surface antigen CD33 modulators), CLL-1 modulators(C-Type lectin domain family 12 member A modulators), Natural killer cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | China | 02 Apr 2024 | |
Refractory acute myeloid leukemia | Clinical | China | 12 Jul 2023 | |
Relapsing acute myeloid leukemia | Clinical | China | 12 Jul 2023 |